BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 31306204)

  • 21. Post-ABVD/pre-radiotherapy (18)F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients.
    Ciammella P; Filippi AR; Simontacchi G; Buglione M; Botto B; Mangoni M; Iotti C; Merli F; Marcheselli L; Bisi G; Ricardi U; Versari A
    Br J Radiol; 2016; 89(1061):20150983. PubMed ID: 27022777
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation.
    Bahri H; Laurence L; Edeline J; Leghzali H; Devillers A; Raoul JL; Cuggia M; Mesbah H; Clement B; Boucher E; Garin E
    J Nucl Med; 2014 Nov; 55(11):1786-90. PubMed ID: 25286923
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Usefulness of Machine Learning-Based Evaluation of Clinical and Pretreatment [
    Nakajo M; Kawaji K; Nagano H; Jinguji M; Mukai A; Kawabata H; Tani A; Hirahara D; Yamashita M; Yoshiura T
    Mol Imaging Biol; 2023 Apr; 25(2):303-313. PubMed ID: 35864282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and validation of an
    Wang H; Zhao S; Li L; Tian R
    Eur Radiol; 2020 Oct; 30(10):5578-5587. PubMed ID: 32435928
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intratumoral heterogeneity in
    Molina-García D; García-Vicente AM; Pérez-Beteta J; Amo-Salas M; Martínez-González A; Tello-Galán MJ; Soriano-Castrejón Á; Pérez-García VM
    Ann Nucl Med; 2018 Jul; 32(6):379-388. PubMed ID: 29869770
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The prognostic value of mid- and post-treatment [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET) in indolent follicular lymphoma.
    Lu Z; Lin M; Downe P; Chong S; Ling S
    Ann Nucl Med; 2014 Oct; 28(8):805-11. PubMed ID: 25008291
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intratumoral Heterogeneity of Pretreatment 18F-FDG PET Images Predict Disease Progression in Patients With Nasal Type Extranodal Natural Killer/T-cell Lymphoma.
    Ko KY; Liu CJ; Ko CL; Yen RF
    Clin Nucl Med; 2016 Dec; 41(12):922-926. PubMed ID: 27749404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
    Ding CY; Guo Z; Sun J; Yang WP; Li TR
    Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
    [No Abstract]   [Full Text] [Related]  

  • 29. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk stratification in patients with advanced-stage breast cancer by pretreatment [(18) F]FDG PET/CT.
    Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
    Cancer; 2015 Nov; 121(22):3965-74. PubMed ID: 26249241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Values of Different Evaluation Criteria of Interim
    Zhu LT; Cen XN; Ou JP; Qiu ZX; Wang LH; Liu W; Wang WS; Dong YJ; Liang ZY; Wang MJ; Xu WL; Sun YH; Wang Q; Yin Y; Ren HY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):431-437. PubMed ID: 28446288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 18F-FDG PET is an independent outcome predictor in primary central nervous system lymphoma.
    Kasenda B; Haug V; Schorb E; Fritsch K; Finke J; Mix M; Hader C; Weber WA; Illerhaus G; Meyer PT
    J Nucl Med; 2013 Feb; 54(2):184-91. PubMed ID: 23249539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Zone-size nonuniformity of 18F-FDG PET regional textural features predicts survival in patients with oropharyngeal cancer.
    Cheng NM; Fang YH; Lee LY; Chang JT; Tsan DL; Ng SH; Wang HM; Liao CT; Yang LY; Hsu CH; Yen TC
    Eur J Nucl Med Mol Imaging; 2015 Mar; 42(3):419-28. PubMed ID: 25339524
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Midtreatment ¹⁸F-FDG PET/CT Scan for Early Response Assessment of SMILE Therapy in Natural Killer/T-Cell Lymphoma: A Prospective Study from a Single Center.
    Khong PL; Huang B; Lee EY; Chan WK; Kwong YL
    J Nucl Med; 2014 Jun; 55(6):911-6. PubMed ID: 24819420
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of SUVmax measured by pretreatment 18F-FDG PET/CT in patients with primary gastric lymphoma.
    Hwang JP; Lim I; Byun BH; Kim BI; Choi CW; Lim SM
    Nucl Med Commun; 2016 Dec; 37(12):1267-1272. PubMed ID: 27482643
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic and prognostic value of 18F-FDG PET/CT in recurrent germinal tumor carcinoma.
    Alongi P; Evangelista L; Caobelli F; Spallino M; Gianolli L; Midiri M; Picchio M
    Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):85-94. PubMed ID: 28828589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic Value of Tumor Heterogeneity and SUVmax of Pretreatment 18F-FDG PET/CT for Salivary Gland Carcinoma With High-Risk Histology.
    Cheng NM; Hsieh CE; Liao CT; Ng SH; Wang HM; Fang YD; Chou WC; Lin CY; Yen TC
    Clin Nucl Med; 2019 May; 44(5):351-358. PubMed ID: 30932974
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients.
    Rossi C; Kanoun S; Berriolo-Riedinger A; Dygai-Cochet I; Humbert O; Legouge C; Chrétien ML; Bastie JN; Brunotte F; Casasnovas RO
    J Nucl Med; 2014 Apr; 55(4):569-73. PubMed ID: 24566003
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and prognostic value of 18F-FDG-PET/CT in restaging of pancreatic cancer.
    Albano D; Familiari D; Gentile R; Scalisi S; Midiri F; Messina M; Spada M; Fornito MC; Galia M; Midiri M; Alongi P
    Nucl Med Commun; 2018 Aug; 39(8):741-746. PubMed ID: 29782393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic Value of Radiomic Features of
    Zhou Y; Li J; Zhang X; Jia T; Zhang B; Dai N; Sang S; Deng S
    Front Oncol; 2022; 12():834288. PubMed ID: 35198451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.